Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 10 / 16 / 2021

ORIGINAL ARTICLE

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B

Tingshan He, Jing Li, Yanling Ouyang, Guotao Lv, Xiaofeng Ceng, Zhiqiao Zhang and Jianqiang Ding

Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China
Department of Pathology, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China

*Correspondence to:Jianqiang Ding, Department of Infectious Diseases, Shunde Hospital, Southern Medical University, 1#Jiazi Road, Shunde, Guangdong 528308, China. Tel: +86-15218853076, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Zhiqiao Zhang, Department of Infectious Diseases, Shunde Hospital, Southern Medical University, 1#Jiazi Rd, Shunde, Guangdong 528308, China. Tel: +86-15876129625E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(2):113-119 DOI: 10.14218/JCTH.2019.00053
Received: October 14, 2019 Accepted: March 18, 2020 Published online: April 28, 2020

Abstract

Background and Aims: FibroScan is used to determine liver stiffness and controlled attenuation parameter (referred to as CAP) scores in patients, including those with chronic hepatitis B (CHB). We used FibroScan to detect the incidence of fatty liver and fibrosis in CHB patients, and to assess the correlation of FibroScan measurements with blood chemistry tests.

Methods: CHB patients enrolled in this study were divided independently for three separate analyses (of fibrosis, cirrhosis, and fatty liver) based on FibroScan results. Basic information, blood chemistry test results, liver fibrosis parameters, and FibroScan results were collected. T-tests and Pearson’s analyses were used to analyze the correlations between FibroScan liver stiffness measurement/CAP values and liver function, blood fat, uric acid metabolite, fibrosis, and hepatitis B virus load.

Results: A total of 2266 CHB patients were enrolled in the study and divided into three groups: non-significant and significant fibrosis; non-cirrhosis and early cirrhosis; and non-fatty and fatty liver. Spearman’s statistical analyses showed that liver stiffness measurement or CAP values correlated with sex (r=0.137), age (r=0.119),glutamic-pyruvic transaminase (r=0.082), glutamic-oxaloacetic transaminase (r=–0.172), gamma-glutamyltransferase (r=0.225), albumin (r=0.150), globulin (r=–0.107), total bilirubin (r=–0.132), direct bilirubin (r=–0.145), white blood cell count (r=0.254), hemoglobin (r=0.205), platelets (r=0.206), total cholesterol (r=0.214), high density lipoprotein (r=–0.243), low density lipoprotein (r=0.255), apolipoprotein B (r=0.217), hyaluronic acid (r=–0.069), laminin (r=–0.188), procollagen type IV (r=–0.067)and hepatitis B viral DNA load (r=–0.216).

Conclusions: FibroScan is a non-invasive device that can detect the occurrence of fatty liver or liver fibrosis in CHB patients.

Keywords

FibroScan, Chronic hepatitis B, Fatty liver, Liver fibrosis, Cirrhosis

Journal of Clinical and Translational Hepatology 2020 vol. 8, 113-119  [ Html ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

REVIEW ARTICLE

What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist’s Perspective

Nahum Méndez-Sánchez, Alejandro Valencia-Rodríguez, Xingshun Qi, Eric M. Yoshida, Manuel Romero-Gómez, Jacob George, Mohammed Eslam, Ludovico Abenavoli, Weifen Xie, Rolf Teschke, Andres F. Carrion and Andrew P. Keaveny

Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico
Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly General Hospital of Shenyang Military Area), Shenyang, China
Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada
UCM Digestive Diseases and CIBERehd, Institute of Biomedicine of Seville (IBiS), SeLiver Group, Virgen del Rocío University Hospital, University of Seville, Seville, Spain
Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, NSW, Australia
Department of Health Sciences, University Magna Graecia of Catanzaro, Italy
Department of Gastroenterology, Changzheng Hospital of the Second Military Medical University, Shanghai, China
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Academic Teaching Hospital of the Medical Faculty, Goethe University Frankfurt/Main, Hanau, Germany
10 Division of Gastroenterology and Hepatology, University of Miami, Miller School of Medicine, Miami, FL, USA
Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA

*Correspondence to: Nahum Méndez-Sánchez, Liver Research Unit, Medica Sur Clinic and Foundation, National Autonomous University of Mexico, Puente de Piedra 150, Col. Toriello Guerra, ZP 14050, México City, México. Tel: +525-55424-4629E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(2):109-112 DOI: 10.14218/JCTH.2020.00024
Received: April 4, 2020 Accepted: April 5, 2020 Published online: April 11, 2020

Abstract

As of today, March 30, 2020, when this Editorial is being written, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causal agent of the coronavirus disease (COVID-19) has been confirmed in more than 745,000 cases worldwide and has claimed the lives of more than 35,000 people.1 In addition to the morbidity and mortality associated with COVID-19, this betacoronavirus has placed several of the world’s major economies in strife, mainly in Western Europe and North America, paralyzing travel and regular social interactions, making COVID-19 undoubtedly one of the most important pandemics in human history.

While we are in the midst of battling this pandemic, we have already learned some lessons from a cruel teacher: a) the importance of a strong association that must exist between governments and the scientific community in implementing a broad range of measures to contain and, in the future, prevent this type of epidemic; b) the potential for this pandemic to indirectly, due to less available resources, increase liver-related outcomes morbidity and mortality, including liver transplantation; c) the necessity to develop new working practices in multidisciplinary teams that will provide appropriate levels of care for patients from intensive care units to the outpatient setting. COVID-19 may make virtual clinic visits through telemedicine the norm and not the exception in some parts of the world. However, there are many questions that have yet to be answered. One of the most important to resolve is the understanding of the devastating impact of SARS-CoV-2 in specific geographic regions, such as Spain and Italy.

 

Journal of Clinical and Translational Hepatology 2020 vol. 8, 109-112  [ Html ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

REVIEW ARTICLE

Pathogenesis of Thrombocytopenia in Chronic HCV Infection: A Review

Sarah Rawi and George Y Wu

Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA

*Correspondence to: Sarah Rawi, Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06032, USA. Tel: +1-858-692-2372E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(2):184-191 DOI: 10.14218/JCTH.2020.00007
Received: January 30, 2020 Accepted: March 31, 2020 Published online: April 15, 2020

Abstract

A large proportion of patients with chronic hepatitis C have associated thrombocytopenia (TCP). Due to bleeding risks, TCP, when severe, can limit diagnostic and therapeutic procedures, treatments, and increases risk of complications, especially excessive bleeding. It is important to understand the mechanisms that cause TCP in order to manage it. In general, TCP can be due to increased destruction or decreased production. Proposed mechanisms of increased destruction include autoantibodies to platelets and hypersplenism with sequestration. Proposed mechanisms of decreased production include virus-induced bone marrow suppression and decreased TPO production. Autoantibodies directed against platelet surface antigens have demonstrated an inverse correlation with platelet counts. Hypersplenism with sequestration involves the interaction of portal hypertension, splenomegaly, and platelet destruction. Decreased production mechanisms involve appropriate and inappropriate levels of TPO secretion. There is limited evidence to support viral-induced bone marrow suppression. In contrast, there is strong evidence to support low levels of TPO in liver failure as a major cause of TCP. TPO-agonists, specifically eltrombopag, have been shown in hepatitis C patients to increase platelet counts without reducing portal hypertension or splenomegaly. We conclude that TCP in hepatitis C virus-induced liver disease is often multifactorial, but an understanding of the mechanisms can lead to judicious use of new drugs for treatment.

Keywords

Thrombocytopenia, Chronic hepatitis, Autoantibodies, Hypersplenism, Thrombopoietin

Journal of Clinical and Translational Hepatology 2020 vol. 8, 184-191  [ Html ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

 logo

You are here: Home Archive Vol 8 Issue 2